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METHODS AND MATERIALS: A healthy 57-year-old man presented with high-risk prostate
cancer (Gleason score of 8, prostate-specific antigen level [PSA] 12.6 ng/mL, T3a by magnetic
resonance imaging [MRI]), only 2.5 years after a low anterior resection followed by pelvic
chemo-radiotherapy to 50.4 Gy for a locally advanced rectal cancer. Due to the prior radiation,
he was not felt to be a candidate for surgery or external beam radiation, so he chose long-term
androgen deprivation therapy (ADT) plus high-dose-rate brachytherapy to 36 Gy in 6 fractions.
To reduce the radiation dose to the anterior rectal wall, 10 mL of a polyethylene glycol hydrogel
spacer was injected between the prostate and rectum and created between 1.4 and 1.5 cm of sepa-
ration along the length of the prostate.
RESULTS: Two randomized trials demonstrating that local therapy plus ADT improves overall
survival compared to ADT alone provided the rationale for additional prostate radiotherapy in this
otherwise healthy patient. Salvage brachytherapy is associated with a 3.4% rate of rectal fistula
among the 251 cases reported in the literature from 2000e2007, with rates as high as 12% in
one series. The spacer allowed the rectal dose constraint goals to be easily met.
CONCLUSIONS: Injecting an absorbable polyethylene glycol hydrogel to separate the prostate
and rectum appears to be associated with decreased maximum and mean rectal doses, and may have
particular utility in previously irradiated patients.  2013 American Brachytherapy Society. Pub-
lished by Elsevier Inc. All rights reserved.Keywords: Prostate cancer; Salvage radiotherapy; Hydrogel; SpacerCase report
Presentation
The patient is a physically fit 57-year-old gentleman who
had been diagnosed with a rectal cancer 3 years before
presentation, for which he underwent a low anterior resectionmber 2011; accepted 13 March 2012.
st: None.
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te, Brigham and Women’s Cancer Center, Harvard
Francis Street, Boston, MA 02115. Tel.: þ1-617-
7-975-0912.
nguyen@lroc.harvard.edu (P.L. Nguyen).
nt matter  2013 American Brachytherapy Society. Publis
.1016/j.brachy.2012.03.005showing a pT3N0 tumor with negative margins but extra-
mural venous invasion. The patient underwent adjuvant
capecitabine chemotherapy plus pelvic radiation of 45 Gy
in 1.8 Gy fractions followed by a rectal boost to a total dose
of 50.4 Gy, all of which was completed 2.5 years before the
presentation.
Eighteen months before the presentation, his routine
prostate-specific antigen (PSA) was 2.6 ng/mL, but 8months
before the presentation, it rose to 8.5 ng/mL,which prompted
an ultrasound-guided biopsy that was negative. PSA
continued to rise to 12.6 ng/mL at 4 months before presenta-
tion, prompting a second biopsy that revealed Gleason
4þ 45 8 prostate cancer in 1 of 12 cores. Digital rectal
hed by Elsevier Inc. All rights reserved.
78 P.L. Nguyen et al. / Brachytherapy 12 (2013) 77e83examination was negative. A 3-Tesla endorectal coil MRI
revealed a 25 cc prostate with intermediate T2 signal,
restricted diffusion, and early enhancement at the left base
consistent with prostate cancer with extracapsular extension.
The left seminal vesicle was thickened but not definitely
involved. In addition, in the anterior gland from mid to apex,
there was a 1.9 1.5 cm focus highly suspicious for prostate
cancer with anterior extracapsular extension.
The patient was evaluated by an experienced urologic
oncologist who felt that with the extent of disease, surgery
was not a good option because it was likely noncurative and
would pose a high risk of complications owing to the prior
pelvic radiation.Therapeutic plan
After multidisciplinary consultation, the patient elected
to proceed with a long-term (2e3 years) androgen
deprivation therapy (ADT) plus radiation in the form of
high-dose-rate (HDR) prostate brachytherapy delivered
over two implants in a conformal fashion to target the
prostate and areas of extracapsular disease. Given that
additional radiation dose to the rectum would put the
patient at risk for rectal injury and potentially colostomy,
he elected to travel to the Department of Urology,
University of Heidelberg, Germany, for placement of
a polyethylene glycol (PEG) hydrogel spacer (Space-
OAR; Augmenix Inc., Waltham, MA, USA) between
the prostate and rectum that is intended to absorb in
about 6 months but has not yet been approved by the
Food and Drug Administration in the United States.Fig. 1. Transrectal ultrasound images of prostate before (a) and after (c, d; axial
the space between Denonvilliers’ fascia and anterior rectal wall.Injection of hydrogel
Ten milliliters of spacer hydrogel were injected from
a transperineal approach with transrectal ultrasound guid-
ance and under intravenous sedation. The patient was posi-
tioned in lithotomy position. The injection needle (18G)
was inserted perineally and carefully driven to the space
between Denonvilliers’ fascia and the anterior rectal wall.
To create enough space for the spacer gel and to ensure
steady dispersion, the space was dissected, using 25 mL
of injectable saline (‘‘hydrodissection’’). After ensuring
the correct position of the needle and suitable space, the
hydrogel was administered. The distance of rectal wall to
prostate/Denonvilliers’ fascia was measured before and
after spacer hydrogel injection and showed a gain of
14e15 mm owing to the spacer hydrogel (Fig. 1), which
could be confirmed on MRI. An axial T2-weighted image
of the patient’s prostate and rectal area before and after
spacer injection are shown in Fig. 2. The total intervention
time for spacer injection was 5 min.HDR brachytherapy procedure
The patient received 2 months of neoadjuvant ADT
before the procedure. Consistent with two previous reports
from the University of California at San Francisco (UCSF)
of patients who received HDR monotherapy for prostate
cancer after prior pelvic radiation, we delivered 36 Gy in
six fractions of 6 Gy each, which is estimated to be biolog-
ically equivalent to a dose of 72 Gy in 2 Gy daily fractions
(1, 2). Two separate implants were performed. After eachand sagittal) hydrogel injection and (b) showing hydrodissection to open up
Fig. 2. (a) T2-weighted axial endorectal coil MRI before spacer injection showing almost no separation between prostate and rectum. (b) T2-weighted axial
MRI after spacer injection showing new separation between prostate and rectum.
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day, followed by a morning and afternoon fraction 6 h apart
on the next day. Catheters were placed throughout the pros-
tate and into the left seminal vesicle, and then inverse plan-
ning simulated annealing was performed to deliver 6 Gy
per fraction to the prostate planning target volume, while
minimizing dose to the urethra, rectum, and bladder.Impact of spacer on dosimetry
As shown in Table 1, both implants met the UCSF goals of
treating at least 90% of the target to 100% of the prescription
dose and keeping less than 1 cc of the urethra above 120% of
the prescription dose. To get adequate coverage on the left
seminal vesicle and left base, 1.2 cc of the bladder was al-
lowed to receive 75% of the prescription dose, slightly
exceeding the 1 cc goal. However, there was a dramatic dosi-
metric decrease in the rectum owing to the spacer. Although
the goal was to keep less than 1 cc of the rectum to 75%of the
dose, there were 0 cc of rectum receiving 75% of the dose, as
seen in Fig. 3, where the 75% isodose line is entirely within
the spacer and does not touch the rectum. A small amount of
the rectumwas within the 50% isodose line, and the radiation
dose to the hottest 2 cc of the rectumwas approximately 3 Gy
per fraction.Table 1
Desired and achieved dosimetric parameters
UCSF goals
Target PTV
V100O90%
Urethra
V120!1 cc
Bladder
V75!1 cc
Rectum
V75!1 cc
Implant 1 97 0.4 1.2 0
Implant 2 92 0.48 1.2 0
UCSF5University of California at San Francisco; PTV5 planning
target volume; V1005 percent volume of the structure receiving 100% of
the prescription dose.Followup
The patient had no urinary frequency, nocturia, or hema-
turia. Nine months after implant, the patient developed mild
rectal bleeding which was eventually treated with argon
plasma coagulation at month 12.Discussion
Prostate cancer treatment options after prior pelvic
radiotherapy
For men who develop prostate cancer after prior pelvic
radiotherapy, the available treatment options are limited
(3). Most of the world’s literature on the subject is from
men who received prior radiation for prostate cancer
(typically to a dose of approximately 70 Gy) and then
recurred. Major approaches that have been attempted with
curative intent include radical prostatectomy, brachytherapy,
and cryotherapy. Performing a salvage radical prostatectomy
in a radiated field can be difficult and lead to high complica-
tion rates. Series have reported up to a 67% rate of some
degree of incontinence (4), 15% rate of rectal injury (5),
and 29% rate of bladder neck stricture (4). Of all 531 cases
of salvage prostatectomy that had been published in the
English literature from 1990 to 2007, the rate of incontinence
was 41%, rectal injury was 4.7%, and bladder neck stricture
was 24% (3). Cryotherapy is not widely used as a first-line
option for the definitive treatment of prostate cancer, and it
is unknown whether its efficacy would be similar to surgery
or radiotherapy. In the postradiation setting, cryotherapy has
been associated with up to a 96% rate of incontinence (6),
a 55% rate of urethral sloughing (6), 55% rate of bladder
stricture (7), 44% rate of perineal pain (8e10), and 11% rate
Fig. 3. (a) Axial image of high-dose-rate (HDR) plan. Prostate (red ), spacer (light blue), and rectum (brown) are contoured. None of the rectum is exposed
to the 75% isodose line ( purple), which is contained entirely in the spacer. A small portion of the anterior rectum is exposed to the 50% isodose line (dark
blueeoutermost isodose line). (b) Sagittal image of HDR Plan. Prostate (red ), spacer (light blue), and rectum (brown) are contoured. None of the rectum is
exposed to the 75% isodose line ( purpleesecond-outermost isodose line), which is contained entirely in the spacer. A small portion of the anterior rectum is
exposed to the 50% isodose line (dark blueeoutermost isodose line).
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reported from 1990 to 2007, a weighted average of morbidity
yields a 36% rate of incontinence, a 11% rate of urethral
sloughing, 17% rate of bladder stricture, 36% rate of perineal
pain, and 2.6% rate of fistula (3). Salvage brachytherapy after
prior radiotherapy has also been reported, either as low-dose-
rate seed implantation or HDR implantation of empty cathe-
ters intowhich a highly active radioactive source is placed for
precise amounts of time to create the appropriate dose distri-
bution. Salvage brachytherapy has been associatedwith up to
a 31% incontinence rate (11), 24%Grade 3 or 4 rectal toxicity
rate (12), 47%Grade 3e4 urinary toxicity rate (13), and 12%
rate of rectal fistula requiring colostomy (12). Of the 251
cases of salvage brachytherapy reported in the literature from
1990 to 2007, the weighted average rate of incontinence was
6%, Grade 3e4 rectal toxicity was 5.6%, Grade 3e4 urinary
toxicity was 17%, and fistula was 3.4% (3).
Local therapy improves survival when added to ADT
This particular patient presented with extracapsular exten-
sion, Gleason score of 8, and PSA level of 12.6 ng/mL. Given
the patient’s good overall health state and long life expectancy,
we felt that some typeof local treatmentwas important, in light
of the two recent randomized trials showing that for patients
with locally advanced prostate cancer, local radiation plus
ADT improves overall survival compared with ADT
alone. Specifically, the Scandinavian Prostate Cancer Group
(SPCG)-7/Swedish Association for Urologic Oncology
(SFUO)-3 trial randomized 875 men with locally advanced
prostate cancer (78% of men had T3 disease) to ADT radi-
ation and found that radiation cut the relative risk of death by
32% among men with a 10-year minimum life expectancy
(overall mortality at 10 years was 39.4% vs. 29.6% favoring
the combined modality arm) (14). Similarly, the Intergroup
trial (National Cancer Institute of Canada-Clinical Trials
Group [NCIC-CTG], Southwest Oncology Group [SWOG],
Medical Research Council of the United Kingdom [MRC-UK], INT: T94-0110; NCT00002633) presented by Warde
et al. (15) at ASCO 2010 randomized 1205 men with locally
advanced disease and found that the addition of radiation to
ADT reduced the relative risk of death by 23%.
HDR as monotherapy in the de novo and salvage
settings
There is both a radiobiologic and dosimetric rationale
for considering HDR brachytherapy for prostate cancer.
The a/b ratio of the prostate has been commonly estimated
to be less than 2, and certainly lower than that of the
rectum, which suggests that the hypofractionation achiev-
able with HDR can provide a radiobiologic advantage in
terms of improved tumor control with less or equal risk
of rectal toxicity (16e19). In addition, although a posteri-
orly placed permanent LDR seed cannot be retracted,
HDR dosimetry is much more forgiving of the placement
of catheters because dose can be optimized after placement,
which is particularly important in the salvage setting where
minimizing dose to the rectum is critical.
Currently, HDR brachytherapy is not widely used as
monotherapy for patients with a new diagnosis of prostate
cancer, although there are prospective series as well as Phase
II trials evaluating it. Martinez et al. (20) of William Beau-
mont reported on the first series of 41 patients treated with
HDRmonotherapy to a dose of 3800 cGy treated in four frac-
tions of 950 cGy delivered twice a day over 2 days. They
found excellent dosimetric coverage of the gland with good
urethral and rectal sparing and a low rate of short-term
morbidity. Martin et al. (21) of Germany also used the same
regimen on 52 patients and reported good dosimetry with
minimal acute toxicity. In addition, Corner et al. (22) re-
ported on a Phase II trial from the United Kingdom that
includes 110 men with locally advanced disease treated with
HDRmonotherapy to doses of 34 Gy in four fractions, 36 Gy
in four fractions, or 31.5 Gy in three fractions. The rate of
acute urinary retention requiring catheterization was 6.4%,
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months (34 Gy), 18 months (36 Gy), and 11.8 months
(31.5 Gy). Also, Yoshioka et al. (23) has reported on
a Japanese series of 112 men treated with hormonal therapy
andHDRmonotherapy to 54 Gy in nine fractions over 5 days
in which the 5-year PSA failure-free survival was 83%
despite more than one-half of the patients having high-risk
disease. Finally,Mark et al. (24) of Lubbock, Texas have pre-
sented in abstract form on their large series of 312 HDR
monotherapy patients treated to 4500 cGy in six fractions
to the prostate and seminal vesicles given as two implants
of three fractions each, spaced 4 weeks apart. None of the
patients received ADT, and with a median followup of
8.2 years, the PSA failure-free survival was 84.6%.
In the setting of prior pelvic radiation, UCSF investigators
have published two series using a regimen of 36 Gy in six
fractions given as three fractions per implants, with the
implants being spaced 1 week apart. The first series by Lee
et al. (1) in 2007 detailed 21 patients who had received prior
external beam radiation (19) or LDR brachytherapy (2) for
prostate cancer and developed a biopsy-proven local recur-
rence at an average of 5.25 years after initial radiation. Nine
of the patients had extracapsular extension or seminal vesicle
invasion. Eleven received neoadjuvant ADT before salvage
HDR. The 2-year PSA failure-free survival was 89% and
the maximum gastrointestinal toxicity was only Grade 2,
but the median followup was only 18.7 months. The second
series by Jabbari et al. (2) was of 6 patients who developed
prostate cancer after receiving a prior abdominopelvic resec-
tion. All had received prior pelvic radiotherapy to a median
dose of 45 Gy (range, 21e73.8 Gy).With a median followup
of 26 months (range, 14e60months), no patient had experi-
enced a biochemical recurrence, and none had higher than
a Grade 3 acute toxicity, although 1 patient developed
a urethral stricture that required dilation.Predictors of fistula after salvage brachytherapy
Rectal fistula is a very rare complication of primary bra-
chytherapy in patients who have not received prior radia-
tion (25). However, it has been reported in 3.4% of the
251 cases of salvage brachytherapy reported in the litera-
ture from 1990 to 2007. The DanaeFarber Phase I/II study
identified an interval to reirradiation of less than 4.5 years
as a risk factor for developing a fistula, which placed our
patient at higher risk because his interval to reirradiation
was only 2.5 years. However, no dosimetric risk factors
for fistula have been identified in this setting, and therefore
the goal was to keep the rectal dose as low as possible.Clinical utility of rectal spacers
The rapid dose falloff with bothHDRandLDRbrachyther-
apy mean that a small amount of space between the prostate
and rectum can potentially greatly lower the rectal dose. Thus
far, the literature has suggested that space created byabsorbable biomaterials between the prostate and rectum can
potentially lead to a reduction in acute toxicity. In 2007, Prada
et al. (26) reported on 27 patients in whom a hyaluronic acid
injection created a median of 2 cm of space between the pros-
tate and rectum without causing acute side effects and led to
a 28% reduction in the maximum rectal dose during an HDR
brachytherapy boost. The same group performed a clinical
trial of 69 patients receiving LDR monotherapy in which the
36 patients who received the spacer had a significantly lower
risk of rectal mucosal damage at the planned proctoscopic
examinations (5% vs. 36%, p!0.002) (27). The group from
Cancer Centers of Irvine has reported on 10 patients who
had a median of 1.3 cm of space from a cross-linked hyalur-
onan gel spacer before HDR brachytherapy (2200 cGy) with
supplemental intensity-modulated radiation therapy (IMRT)
(5040 cGy) and found no Grade 1, 2, or 3 acute diarrhea,
compared with 29.7% among historical controls ( p5 0.04)
(28). The same group also reported on 30 patients who
received the same gel spacing and found that those patients
reported an improved Expanded Prostate Cancer Index
Composite Bowel Bother scores ( p5 0.03) compared with
controls who did not receive the spacer (29).
A recently published study by Noyes et al. (30) reported
on the investigational use of human collagen to increase the
distance between the prostate and the anterior rectal wall.
Before the start of a course of 75.6 Gy IMRT for prostate
cancer, 11 patients were injected through a transperineal
approach with 20 mL of human collagen into the perirectal
space, resulting in mean separation between the prostate
and anterior rectum of 12.7 mm with a mean reduction in
dose to the anterior rectal wall of 50%. All patients denied
any rectal symptoms during the study.
More recently PEG has been used to increase distance
between the rectum and the prostate. Noyes et al. (30) have
suggested that PEGorhydrogel productsmayhave advantages
over hyaluronic acid for this application because hyaluronic
acid appears to be more viscous and may not distribute as
evenly and may be susceptible to radiation degradation (31).
Tokita et al. (32) from theCancerCenter of Irvine reported
on the use of a PEG spacer as a viablemeans to enhance rectal
dose sparing. Twenty-four combined HDR brachytherapy
and IMRT patients were administered the spacing material
in the prostate rectal interspace transperineally at the time
of catheter implantation. Results showed an increase in the
mean prostate rectal spacing of 0.8e0.9 cm and an average
decrease in rectal V70 from 41.4% to 33.6%with a maximum
rectal dose decrease of 36.6%. The same group reported
on 34 patients treated with either HDR brachytherapy
plus IMRT or IMRT alone who were administered PEG to
generate a 1.0 cm mean separation between the prostate
and rectum, resulting in a decrease in themaximumandmean
rectal dose by 11.5% and 30.0%, respectivelywith rectal wall
V70 decreasing by 19.8%, respectively (33).
The group from Johns Hopkins injected PEG into
10 cadavers and were able to generate 1.25 cm of space
between the prostate and rectum, which reduced the
82 P.L. Nguyen et al. / Brachytherapy 12 (2013) 77e83theoretical rectal V70 from IMRT from 19.9% to 4.5% ( p!
0.05) (34).
Pinkawa et al. (35) reported on pilot study results from
a single site (Aachen) of a multisite investigation of a PEG
spacing biomaterial. Before receiving IMRT in doses up to
78 Gy in 2 Gy fractions, 18 patients were injected with the
hydrogel under ultrasound (transrectal ultrasound) guidance
after dissecting the space between the prostate and rectum
with saline. Injecting the hydrogel resulted in a prostate to
rectum distance of 10 4 mm at the base, 9 3 mm in the
midplane, and 11 7 mm at the apex. The portion of the
rectum within the 75 Gy, 70 Gy, and 60 Gy isodose was
decreased by 76%, 59%, and 36% on average, respectively.
Summary and conclusions
Patients who develop a local recurrence or a new diag-
nosis of prostate cancer after prior pelvic radiotherapy have
few good options for local salvage therapy. Salvage brachy-
therapy has been associated with a risk of rectal complica-
tions, including fistula. PEG hydrogel was used in the
current case to create 1.5 cm of space between the prostate
and rectum, allowing the rectal dose to be significantly
lower than previously published dosimetric goals with
HDR salvage brachytherapy. Prostateerectal spacing with
absorbable spacer material may allow for safer administra-
tion of salvage brachytherapy in select patients with locally
recurrent prostate cancer or a new diagnosis after prior
pelvic radiotherapy.Acknowledgments
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